{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'related diseases. The final list of genes to be evaluated will be determined at the time of analysis', 'to be able to account for the most current research.', '95']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.', 'STATISTICS', 'This section describes the statistical analysis as foreseen at the time of planning the study.', 'Changes, additions, and further details about the analyses will be described in the statistical', 'analysis plan. After finalization of the statistical analysis plan, any additional analyses or', 'changes to analyses that may be required will be fully disclosed in the clinical study report.', '9.1.', 'Sample Size and Power Considerations', 'It is estimated that approximately 58 patients per arm will enable a power of at least 90% to', 'detect a beneficial standardized effect of 63% or more when the TEV-50717 arm is compared to', 'placebo (difference of 6.0 in the change from baseline to week 12 in TTS, assuming a standard', 'deviation of 9.5 in each arm) in a 2-sided type I error rate of 5% after accounting for potential', 'dropouts.', '9.2.', 'Analysis Sets', '9.2.1.', 'Intent-to-Treat Analysis Set', 'The intent-to-treat (ITT) analysis set will include all randomized patients. In this population,', 'treatment will be assigned based on the treatment to which patients were randomized, regardless', 'of which treatment they actually received.', '9.2.2.', 'Safety Analysis Set', 'The safety analysis set will include all patients who receive at least 1 dose of IMP. In this', 'population, treatment will be assigned based upon the treatment patients actually receive,', 'regardless of the treatment to which they were randomized.', '9.2.3.', 'Modified Intent-to-Treat Analysis Set', 'The Modified Intent-to-Treat (mITT) analysis set will include all patients in the ITT population', 'who receive at least 1 dose of IMP and have both a baseline and at least 1 post-baseline YGTSS', 'assessment. In this population, treatment will be assigned based on the treatment to which', 'patients were randomized, regardless of which treatment they actually received. All primary and', 'secondary analyses will be based on the mITT set.', '9.2.4.', 'Per-Protocol Analysis Set', 'The per-protocol analysis set will include patients who are compliant with study medication', '(80% to 105%), have a YGTSS assessment at baseline and at week 9 or week 12, who have not', 'taken prohibited concomitant medications as indicated in exclusion criterion, and who have no', '96']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'major protocol deviations that affect the validity of the efficacy measurements. The list of', 'protocol deviations will be reviewed before unblinding and major protocol deviations that could', 'affect the primary and secondary variables will be determined. All exclusions from the per-', 'protocol analysis set will be reviewed in the blinded data review meeting before database lock.', '9.3.', 'Data Handling Conventions', 'For all variables, only the observed data from the patients will be used in the primary and', 'secondary statistical analyses.', '9.4.', 'Study Population', 'The mITT analysis set (see Section 9.2) will be used for all efficacy summaries and analyses', 'unless otherwise noted. The safety analyses set will be used for all safety summaries. Sensitivity', 'analyses of primary and key secondary endpoints will be conducted using the per-protocol', 'analysis set. Summaries will be presented by treatment group and for all patients.', '9.4.1.', 'Patient Disposition', 'Data from patients screened; patients screened but not randomized (and reason not randomized);', 'patients who are randomized; patients randomized but not treated (and reason); patients in the', 'ITT, safety, and other analysis sets; patients who complete the study; and patients who withdraw', 'from the study will be summarized using descriptive statistics. Data from patients who withdraw', 'from the study will also be summarized by reason for withdrawal using descriptive statistics.', '9.4.2.', 'Demographic and Baseline Characteristics', 'Patient demographic and baseline characteristics, including medical history, prior medications,', 'and ECG findings, will be examined to assess the comparability of the treatment groups and will', 'be summarized using descriptive statistics. For continuous variables, descriptive statistics', '(number [n], mean, standard deviation, median, minimum, and maximum) will be provided. For', 'categorical variables, patient counts and percentages will be provided. Categories for missing', 'data will be presented if necessary.', '9.5.', 'Efficacy Analysis', '9.5.1.', 'Primary Endpoint', 'The primary efficacy endpoint for this study is the change in the TTS (of the YGTSS) from', 'baseline to week 12.', '9.5.2.', 'Key Secondary Enppoints', 'Key secondary endpoints for this study are as follows:', '1.', 'Change in the TS-CGI score from baseline to week 12', '2. Change in the TS-PGII score from baseline to week 12', '3. Change in the C&A-GTS-QOL ADL subscale score from baseline to week 12', '97']\n\n###\n\n", "completion": "END"}